Regerna Therapeutics, Inc.

Building on a deep understanding of mRNA binding proteins, Regerna Therapeutics has pioneered the use of AUF1 as a master regulator of functional muscle regeneration and repair. We are developing therapeutics for surgical and post-injury disuse atrophy (LNP-delivered AUF1, REG-1003) as well as muscular dystrophies (AAV8-delivered AUF1, REG-A40), all area of high unmet need. This brings us directly into the healthy aging and longevity fields – but importantly with clearly defined and highly focused clinical development and product lifecycle pathways. Consistent AUF1 pre-clinical data across multiple animal models, delivery methods and dosing periods show clear restoration of all parameters of active, fully functional muscle as well as significant improvement of clinically relevant performance measurements such as strength and endurance.